Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

1569 ARTÍCULOS , VIENDO DEL 976 AL 990

Data-driven identification of endophenotypes of Alzheimer's disease progression: implications for clinical trials and therapeutic interventions

Geifman N, Kennedy RE, Schneider LS, Buchan I, Brinton RD.

Alzheimers Res Ther. 2018 Jan 15;10(1):4. doi: 10.1186/s13195-017-0332-0.

Exercise Training on Locomotion in Patients with Alzheimer's Disease: A Feasibility Study

Pedrinolla A, Venturelli M, Fonte C, Munari D, Benetti MV, Rudi D, Tamburin S, Muti E, Zanolla L, Smania N, Schena F.

J Alzheimers Dis. 2018;61(4):1599-1609. doi: 10.3233/JAD-170625.

Safety, tolerability and immunogenicity of an active anti-Aβ(40) vaccine (ABvac40) in patients with Alzheimer's disease: a randomised, double-blind, placebo-controlled, phase I trial

Lacosta AM, Pascual-Lucas M, Pesini P, Casabona D, Pérez-Grijalba V, Marcos-Campos I, Sarasa L, Canudas J, Badi H, Monleón I, San-José I, Munuera J, Rodríguez-Gómez O, Abdelnour C, Lafuente A, Buendía M, Boada M, Tárraga L, Ruiz A, Sarasa M.

Alzheimers Res Ther. 2018 Jan 29;10(1):12. doi: 10.1186/s13195-018-0340-8.

Socioeconomic disparities in clinical trials on Alzheimer's disease: a systematic review

Canevelli M, Bruno G, Vico C, Zaccaria V, Lacorte E, Iavicoli I, Vanacore N, Cesari M.

Eur J Neurol. 2018 Apr;25(4):626-e43. doi: 10.1111/ene.13587. Epub 2018 Feb 26.

Peptides as Potential Therapeutics for Alzheimer's Disease

Ribarič S.

Molecules. 2018 Jan 30;23(2):283. doi: 10.3390/molecules23020283.

Deep Brain Stimulation of Frontal Lobe Networks to Treat Alzheimer's Disease

Scharre DW, Weichart E, Nielson D, Zhang J, Agrawal P, Sederberg PB, Knopp MV, Rezai AR; Alzheimer’s Disease Neuroimaging Initiative.

J Alzheimers Dis. 2018;62(2):621-633. doi: 10.3233/JAD-170082.

Delayed-Start Analyses in the Phase 3 Solanezumab EXPEDITION3 Study in Mild Alzheimer's Disease

Liu-Seifert H, Case MG, Andersen SW, Holdridge KC, Aisen PS, Kollack-Walker S, Siemers E.

J Prev Alzheimers Dis. 2018;5(1):8-14. doi: 10.14283/jpad.2018.1.

Research and development of anti-Alzheimer's disease drugs: an update from the perspective of technology flows

Liu K, Lin HH, Pi R, Mak S, Han Y, Hu Y.

Expert Opin Ther Pat. 2018 Apr;28(4):341-350. doi: 10.1080/13543776.2018.1439475. Epub 2018 Feb 13.

Research progress of epigenetic biomarkers in the early diagnosis and treatment of human diseases

Li W, Qin J, Wang H, Chen LB.

Yi Chuan. 2018 Feb 20;40(2):104-115. doi: 10.16288/j.yczz.17-220.

Biomarker pattern of ARIA-E participants in phase 3 randomized clinical trials with bapineuzumab

Liu E, Wang D, Sperling R, Salloway S, Fox NC, Blennow K, Scheltens P, Schmidt ME, Streffer J, Novak G, Einstein S, Booth K, Ketter N, Brashear HR; ELN115727-301/302 Investigator Group.

Neurology. 2018 Mar 6;90(10):e877-e886. doi: 10.1212/WNL.0000000000005060. Epub 2018 Feb 2.

Neurobiological links between depression and AD: The role of TGF-β1 signaling as a new pharmacological target

Caraci F, Spampinato SF, Morgese MG, Tascedda F, Salluzzo MG, Giambirtone MC, Caruso G, Munafò A, Torrisi SA, Leggio GM, Trabace L, Nicoletti F, Drago F, Sortino MA, Copani A.

Pharmacol Res. 2018 Apr;130:374-384. doi: 10.1016/j.phrs.2018.02.007. Epub 2018 Feb 10.

Protective effects of Alpinae Oxyphyllae Fructus extracts on lipopolysaccharide-induced animal model of Alzheimer's disease

Wang Y, Wang M, Fan K, Li T, Yan T, Wu B, Bi K, Jia Y.

J Ethnopharmacol. 2018 May 10;217:98-106. doi: 10.1016/j.jep.2018.02.015. Epub 2018 Feb 12.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias